Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 8/20 | 0.48 |
| ▸ | RAB9A | P51151 | 8/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.48 |
| ▸ | TP53 | P04637 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL413806 | 0.92 | NPC1 (0.48) | NPC1RAB9ASMN1; SMN2TP53ALDH1A1 | |
| SCHEMBL1053854 | 0.85 | NPC1 (0.50) | NPC1RAB9ASMN1; SMN2TP53ALDH1A1 | |
| SCHEMBL1052531 | 0.85 | CYP2C9 (0.47) | SMN1; SMN2ALDH1A1TDP1CYP2C9MAPT | |
| SCHEMBL1050796 | 0.85 | NPC1 (0.49) | NPC1RAB9ASMN1; SMN2TP53ALDH1A1 | |
| SCHEMBL1050450 | 0.84 | CYP2C9 (0.42) | NPC1RAB9ASMN1; SMN2POLBCYP2C9 | |
| SCHEMBL1050290 | 0.84 | CYP2C9 (0.43) | NPC1RAB9ASMN1; SMN2CYP2C9 | |
| SCHEMBL1055048 | 0.84 | BRS3 (0.44) | NPC1RAB9ASMN1; SMN2TDP1CYP2C9 | |
| SCHEMBL415330 | 0.84 | NPC1 (0.48) | NPC1RAB9ASMN1; SMN2TP53ALDH1A1 | |
| SCHEMBL1053841 | 0.84 | NPC1 (0.44) | NPC1RAB9ASMN1; SMN2TP53POLB | |
| SCHEMBL1053298 | 0.83 | CYP2C9 (0.44) | NPC1RAB9ASMN1; SMN2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7872018-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON, INC. (US) | 2011-01-18 | — | — | US | claimed |
| US-20080221148-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC | 2008-09-11 | — | — | US | claimed |
| US-20230020356-A1 | METHODS OF STRATIFYING AND TREATING A SUB-POPULATION OF INFLAMMATORY BOWEL DISEASE PATIENTS | CEDARS-SINAI MEDICAL CENTER | 2023-01-19 | — | — | US | disclosed |
| US-7872018-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON, INC. (US) | 2011-01-18 | — | — | US | disclosed |
| US-20080221148-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221148-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | NPC1 2367/4885RAB9A 1597/4885SMN1; SMN2 1839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.